SG11202002711WA - Cancer score for assessment and response prediction from biological fluids - Google Patents

Cancer score for assessment and response prediction from biological fluids

Info

Publication number
SG11202002711WA
SG11202002711WA SG11202002711WA SG11202002711WA SG11202002711WA SG 11202002711W A SG11202002711W A SG 11202002711WA SG 11202002711W A SG11202002711W A SG 11202002711WA SG 11202002711W A SG11202002711W A SG 11202002711WA SG 11202002711W A SG11202002711W A SG 11202002711WA
Authority
SG
Singapore
Prior art keywords
assessment
biological fluids
response prediction
cancer score
score
Prior art date
Application number
SG11202002711WA
Inventor
Shahrooz Rabizadeh
Patrick Soon-Shiong
Original Assignee
Nantomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantomics Llc filed Critical Nantomics Llc
Publication of SG11202002711WA publication Critical patent/SG11202002711WA/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202002711WA 2017-10-12 2018-10-11 Cancer score for assessment and response prediction from biological fluids SG11202002711WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762571414P 2017-10-12 2017-10-12
PCT/US2018/055481 WO2019075251A2 (en) 2017-10-12 2018-10-11 Cancer score for assessment and response prediction from biological fluids

Publications (1)

Publication Number Publication Date
SG11202002711WA true SG11202002711WA (en) 2020-04-29

Family

ID=66101142

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002711WA SG11202002711WA (en) 2017-10-12 2018-10-11 Cancer score for assessment and response prediction from biological fluids

Country Status (6)

Country Link
US (3) US11810672B2 (en)
CN (1) CN111213209A (en)
AU (1) AU2018348249A1 (en)
CA (1) CA3077221A1 (en)
SG (1) SG11202002711WA (en)
WO (1) WO2019075251A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018348249A1 (en) 2017-10-12 2020-04-16 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids
US11168356B2 (en) * 2017-11-02 2021-11-09 The Chinese University Of Hong Kong Using nucleic acid size range for noninvasive cancer detection
EP3977477A1 (en) * 2019-05-24 2022-04-06 Yeda Research and Development Co. Ltd Method and system for predicting gestational diabetes
US20230020286A1 (en) * 2019-12-24 2023-01-19 E-Solutions,Inc. Health management system and health management method
US20220042109A1 (en) * 2020-08-06 2022-02-10 Agendia NV Methods of assessing breast cancer using circulating hormone receptor transcripts
US20240047033A1 (en) * 2020-12-17 2024-02-08 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Multi-omics methods for precision medicine
WO2023196390A1 (en) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Aneuploidy biomarkers associated with response to anti-cancer therapies
CN114959026A (en) * 2022-04-15 2022-08-30 深圳市陆为生物技术有限公司 Application of reagent for detecting gene in preparation of product for evaluating recurrence risk of breast cancer patient
CN115132327B (en) * 2022-05-25 2023-03-24 中国医学科学院肿瘤医院 Microsatellite instability prediction system, construction method thereof, terminal equipment and medium

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
WO2011149534A2 (en) 2010-05-25 2011-12-01 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
WO2012172575A1 (en) * 2011-06-16 2012-12-20 Decode Genetics Ehf Genetic variants for predicting risk of breast cancer
US9422592B2 (en) 2012-01-06 2016-08-23 Viomics, Inc. System and method of detecting RNAS altered by cancer in peripheral blood
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
EP2971152B1 (en) 2013-03-15 2018-08-01 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
SG10201709537PA (en) 2013-05-30 2017-12-28 Genomic Health Inc Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
KR102441391B1 (en) * 2014-07-25 2022-09-07 유니버시티 오브 워싱톤 Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
MA40737A (en) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
JP2018537128A (en) * 2015-12-03 2018-12-20 アルフレッド ヘルス Monitoring myeloma treatment or progression
US10982286B2 (en) 2016-01-22 2021-04-20 Mayo Foundation For Medical Education And Research Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
BR112018077122A8 (en) * 2016-07-20 2023-01-31 Biontech Rna Pharmaceuticals Gmbh METHODS FOR DETERMINING THE SUITABILITY OF A NEO-Epitope, FOR DETERMINING THE SUITABILITY OF A COMBINATION FOR PROVIDING A VACCINE, FOR PROVIDING A RECOMBINANT IMMUNE CELL, FOR PROVIDING AN IMMUNE RESPONSE, AND FOR TREATMENT OF A MAMMAL WITH A DISEASE, VACCINE AND IMMUNE CELL RECOMBINANT
WO2018231860A1 (en) * 2017-06-12 2018-12-20 Grail, Inc. Alignment free filtering for identifying fusions
AU2018348249A1 (en) 2017-10-12 2020-04-16 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids

Also Published As

Publication number Publication date
AU2018348249A1 (en) 2020-04-16
US20230420137A1 (en) 2023-12-28
CN111213209A (en) 2020-05-29
CA3077221A1 (en) 2019-04-18
US20200335215A1 (en) 2020-10-22
US20240021314A1 (en) 2024-01-18
US11810672B2 (en) 2023-11-07
WO2019075251A3 (en) 2019-07-25
WO2019075251A2 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
SG11202002711WA (en) Cancer score for assessment and response prediction from biological fluids
EP3446247A4 (en) Apparatus and methodologies for personal health analysis
SG10202103903UA (en) Systems and methods for assessing biological samples
IL275698A (en) Systems and methods for treating biological fluids
SG11201706341RA (en) Systems and methods for biological analysis
ZA201800453B (en) Tissue factor pathway inhibitor antibodies and uses thereof
DK3110984T3 (en) MARTENSITIC-FERRITIC STAINLESS STEEL, PROCESSED PRODUCT AND PROCEDURES, WHERE THEY ARE USED ALSO
EP3333276A4 (en) Stainless steel and oil well stainless steel material
EP3634632C0 (en) Biological fluid separation device
SI3256275T1 (en) Ultrasonic grain refining
SG11201800647SA (en) Biological condition determination device and biological condition determination method
GB201413162D0 (en) Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway
GB201609712D0 (en) Disease targets and biomarkers
HK1245060A1 (en) Determination of fertility potential from the oxidation-reduction potential of a biological sample
GB201716240D0 (en) Relevancy assessment and visualization of biological pathways
HK1245778A1 (en) Small molecules for the treatment of primary cancer and cancer metastasis
ZA201802618B (en) Anti-cd43 antibody and use thereof for cancer treatment
GB201511207D0 (en) Isolated organ evaluation and treatment
GB201720426D0 (en) CD47 and BCMA antigen-binding molecules
FR3025978B1 (en) DEVICE FOR DECREASING THE POPULATION OF ASIAN FRELONS
GB2560863B (en) Biological information display apparatus
HUE062208T2 (en) Device for removing undesirable biological and/or chemical entities from biological fluids
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer
GB201416868D0 (en) Mass spectral analysis of urine and other bodily fluids for the detection of cancer biomarkers
PT3607086T (en) Method for analyzing the expression of one or more biomarker rna molecules